Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (PRTO)
Filing Type: Form 8-K (Current Report)
Report Date: October 31, 2019
Reporting Period: Third Quarter ended September 30, 2019
Business Overview: The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Waltham, MA. The company trades on the Nasdaq Capital Market under the symbol PRTO.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves as a notification that financial results for the third quarter of 2019 were announced via a press release (Exhibit 99.1), which is incorporated by reference but not detailed within the body of this specific document.
Material Changes
Comparison to Prior Period: The filing text does not provide data to compare current period performance against prior comparable periods. Specific operational or financial changes are contained within the referenced press release (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary and Outlook: No specific guidance, outlook, or management commentary is included in the text of this Form 8-K. The document directs readers to the attached press release for the announcement of third-quarter results.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information under Item 2.02 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 31, 2019) for actual financial figures, as they are not listed in the 8-K body.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol (PRTO) and exchange (Nasdaq Capital Market) for accurate market data retrieval.
- Note that the financial data in this filing is not deemed "filed" under Section 18 of the Exchange Act, limiting liability exposure for the specific figures referenced.